KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares: 2010-2025

Historic Treasury Shares for Pacira BioSciences (PCRX) over the last 5 years, with Sep 2025 value amounting to $125.5 million.

  • Pacira BioSciences' Treasury Shares rose 399.75% to $125.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.5 million, marking a year-over-year increase of 399.75%. This contributed to the annual value of $25.1 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Treasury Shares is $4.8 million, which was up 70.76% from $2.8 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Treasury Shares high stood at $4.8 million for Q3 2025, and its period low was $837,000 during Q2 2024.
  • Over the past 3 years, Pacira BioSciences' median Treasury Shares value was $1.1 million (recorded in 2023), while the average stood at $1.7 million.
  • Data for Pacira BioSciences' Treasury Shares shows a peak YoY soared of 399.75% (in 2025) over the last 5 years.
  • Pacira BioSciences' Treasury Shares (Quarterly) stood at $25.1 million in 2024, then skyrocketed by 399.75% to $125.5 million in 2025.
  • Its last three reported values are $125.5 million in Q3 2025, $75.5 million for Q2 2025, and $25.1 million during Q1 2025.